<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971019</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-SBSBC</org_study_id>
    <nct_id>NCT03971019</nct_id>
  </id_info>
  <brief_title>Survival Benefits of Statins in Breast Cancer Patients</brief_title>
  <acronym>SBSBC</acronym>
  <official_title>Survival Benefits of Statins in Breast Cancer Patients With Abnormal Lipid Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we compared the survival benefit of breast cancer patients with dyslipidemia&#xD;
      (low and medium risk of ASCVD). The control group used dietary intervention instead of&#xD;
      statins intervention. The main endpoint was 5 years DFS. The subjects were breast cancer&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open, blank controlled, single-center clinical trial was conducted to compare&#xD;
      the survival benefits of statins in breast cancer patients with dyslipidemia (low and medium&#xD;
      risk of ASCVD). The control group used dietary intervention instead of statins. The main&#xD;
      endpoint was 3 and 5 years DFS. The subjects were breast cancer patients. In this study, 348&#xD;
      patients were randomly divided into two groups according to patients' wishes and written&#xD;
      informed consent. The experimental group: control group = 1:1. Subjects were screened and&#xD;
      administered continuously until the disease progressed and the toxicity was intolerable.&#xD;
      Informed consent was withdrawn or the researcher decided that the drug must be discontinued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2019</start_date>
  <completion_date type="Anticipated">June 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, open, blank controlled, single-center clinical trial. The control group used dietary intervention instead of statins.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>5 years</time_frame>
    <description>Disease free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>Statin therapy (experimental group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the basis of guiding patients to control their diet and improve their lifestyle, etc.&#xD;
Simvastatin 20mg/d QN Po (dosage can be adjusted according to the blood lipid level of each reexamination) Atorvastatin 10mg/d QN Po (patients who cannot tolerate the side effects of simvastatin may consider replacing this drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietary intervention group (control group)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Guiding patients to control diet, improve lifestyle, etc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>statins</intervention_name>
    <description>On the basis of dietary intervention. Simvastatin 20mg/d QN Po (half an hour before bedtime) (dosage can be adjusted according to other indicators of blood lipid level in each review), atorvastatin 10mg/d QN Po (half an hour before bedtime) (patients who can not tolerate the side effects of simvastatin can consider replacing this drug).</description>
    <arm_group_label>Statin therapy (experimental group)</arm_group_label>
    <other_name>Simvastatin Shu Jiangzhi is manufactured by Merchant Company20mg*14 tablets Dose group: 20 mg once a day before bed</other_name>
    <other_name>Atorvastatin Lipitor, commonly known as Atorvastatin Calcium Tablets, 20mg*7 tablets Dose group: 10 mg once a day before bed</other_name>
    <other_name>Atorvastatin Ale Beijing Jialin Pharmaceutical Co., Ltd. Alatorvastatin Calcium Tablets Specification and packing: 10mg*7 tablets Dose group: 10 mg once a day before bed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary intervention group (control group)</intervention_name>
    <description>Restriction of dietary components that increase LDL-C Saturated Fatty Acids Less than 7% of total energy Dietary cholesterol &lt; 300 mg/d Increasing Dietary Ingredients for Reducing LDL-C Phytosterol 2~3 g/d Water soluble dietary fiber 10~25 g/d total energy Adjusted to maintain ideal weight or lose weight Physical activity Maintain moderate intensity exercise and consume at least 200 kcal of calories per day</description>
    <arm_group_label>Dietary intervention group (control group)</arm_group_label>
    <other_name>Dietary and motor regulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed as invasive breast cancer, it has been treated surgically, confirmed by&#xD;
             histology, cytology or imaging.&#xD;
&#xD;
          2. Female patients (35-75 years old);&#xD;
&#xD;
          3. The low-risk patients with ASCVD are detailed in Annex 1.&#xD;
&#xD;
          4. Signed written informed consent approved by IRB or IEC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subjects were pregnant or lactating.&#xD;
&#xD;
          2. Pregnancy test positive (urine or serum) in women with potential pregnancy within 7&#xD;
             days before administration.&#xD;
&#xD;
          3. Other invasive tumors (including the second primary breast cancer) may affect the&#xD;
             evaluation of outcomes and the compliance of schemes, but subjects who have been cured&#xD;
             and survived disease-free for at least five years can be selected.&#xD;
&#xD;
          4. Patients with chronic underlying liver diseases who have abnormal liver function&#xD;
             and/or clinical manifestations:&#xD;
&#xD;
             Serum total bilirubin &gt; 2.5 *ULN; or INR &gt; 1.5 although there was no increase in&#xD;
             bilirubin Serum ALT or AST &gt; 3 *ULN; Alkaline phosphatase &gt; 2.5 *ULN; Elevated ALT or&#xD;
             AST may gradually recover, but with progressively increased fatigue, nausea and&#xD;
             vomiting, fever, right upper abdominal pain or tenderness.&#xD;
&#xD;
          5. Extremely high risk ASCVD patients Including acute coronary syndrome (ACS), stable&#xD;
             coronary heart disease, revascularization, ischemic cardiomyopathy, ischemic stroke,&#xD;
             transient ischemic attack, peripheral atherosclerosis, etc.&#xD;
&#xD;
          6. High-risk ASCVD patients (in accordance with one of the following circumstances):&#xD;
&#xD;
             LDL-C&gt;4.9 mmol/L or TC&gt;7.2 mmol/L Diabetic patients with 1.8 mmol/L &lt; LDL-C &lt; 4.9&#xD;
             mmol/L (or) 3.1 mmol/L &lt; TC &lt; 7.2 mmol/L and age &lt; 40 years&#xD;
&#xD;
             The 10-year risk of ASCVD was moderate and younger than 55 years old. The remaining&#xD;
             life risk was assessed. Those with any of the following two or more risk factors are&#xD;
             defined as high risk:&#xD;
&#xD;
             Systolic or diastolic blood pressure (&gt; 160 mmHg) or (&gt; 100 mmHg)&#xD;
&#xD;
               -  Non-HDL-C&gt;5.2 mmol/L (200 mg/dl)&#xD;
&#xD;
               -  HDL-C &lt; 1.0 mmol/L (40 mg/dl)&#xD;
&#xD;
               -  BMI&gt;28 kg/m2 Smoking&#xD;
&#xD;
          7. In the abnormal group of simple TG (triglyceride), TG (&gt; 5.7 mmol/L)&#xD;
&#xD;
          8. Other serious diseases, including:&#xD;
&#xD;
             Congestive heart failure (NYHA grade II, III, IV); dyspnea at rest or requiring oxygen&#xD;
             therapy; severe infection; uncontrolled diabetes mellitus;&#xD;
&#xD;
          9. If there are serious mental or mental disorders, it is estimated that the&#xD;
             subjects'compliance to participate in this study is not strong.&#xD;
&#xD;
         10. Drug allergies to research drugs are known.&#xD;
&#xD;
         11. Participated in other drug clinical trials in the past 30 days.&#xD;
&#xD;
         12. Failure to complete at least one cycle of clinical trials based on this protocol, and&#xD;
             failure to evaluate safety and effectiveness.&#xD;
&#xD;
         13. Serious violation of this study program, not in accordance with the prescribed dose,&#xD;
             method and course of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female breast cancer patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuefei Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PUMCH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuefei Wang, M.D.</last_name>
    <phone>008613001289600</phone>
    <email>1210548954@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiang Sun, M.D.</last_name>
    <phone>008618801038718</phone>
    <email>799692578@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PUMCH</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Hui, M.D.</last_name>
      <phone>0086-13810399955</phone>
      <email>pumchkyc@126.com</email>
    </contact>
    <investigator>
      <last_name>Xuefei Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Filippatos TD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP. Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev. 2009 Apr;35(2):175-84. doi: 10.1016/j.ctrv.2008.09.007. Epub 2008 Nov 14. Review.</citation>
    <PMID>19013720</PMID>
  </reference>
  <results_reference>
    <citation>Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011 Jun 20;13(3):R64. doi: 10.1186/bcr2901.</citation>
    <PMID>21689398</PMID>
  </results_reference>
  <results_reference>
    <citation>Beckwitt CH, Brufsky A, Oltvai ZN, Wells A. Statin drugs to reduce breast cancer recurrence and mortality. Breast Cancer Res. 2018 Nov 20;20(1):144. doi: 10.1186/s13058-018-1066-z. Review.</citation>
    <PMID>30458856</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu B, Yi Z, Guan X, Zeng YX, Ma F. The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis. Breast Cancer Res Treat. 2017 Jul;164(1):1-11. doi: 10.1007/s10549-017-4246-0. Epub 2017 Apr 21.</citation>
    <PMID>28432513</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>August 11, 2019</last_update_submitted>
  <last_update_submitted_qc>August 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>statins</keyword>
  <keyword>abnormal lipid metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The results of this study can be shared</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03971019/Prot_SAP_ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

